498548-15-5Relevant articles and documents
QUERCETIN DERIVATIVE, PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME, AND METHOD FOR SYNTHESIZING THE SAME
-
Paragraph 0122-0125; 0135-0138, (2021/01/29)
The present invention relates to a novel quercetin derivative in which a 4′-hydroxy group of quercetin is substituted and which has excellent stability, to a pharmaceutical composition for preventing or treating cancer comprising the same, and to a synthe
Regiospecific synthesis of three quercetin O-β-glucosides of N-acetylglucosamine
Cao, Zhiling,Chen, Jing,Zhu, Dandan,Yang, Zongnan,Teng, Wenqi,Liu, Gaofeng,Liu, Bing,Tao, Chuanzhou
, p. 189 - 193 (2018/05/26)
The regiospecific synthesis of three quercetin O-β-glucosides of N-acetylglucosamine has been achieved in good yield. Selective di- and tri-O-benzylation of quercetin followed by O-glycosylation with 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-d-glucopyranosyl chloride under phase-transfer catalysis conditions yielded, after deacetylation and debenzylation, 3-, 3′- and 4′-glycosylated quercetin.
Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75
Li, Bo-Wen,Zhang, Feng-Hua,Serrao, Erik,Chen, Huan,Sanchez, Tino W.,Yang, Liu-Meng,Neamati, Nouri,Zheng, Yong-Tang,Wang, Hui,Long, Ya-Qiu
, p. 3146 - 3158 (2014/06/09)
HIV integrase (IN) is an essential enzyme for the viral replication. Currently, three IN inhibitors have been approved for treating HIV-1 infection. All three drugs selectively inhibit the strand transfer reaction by chelating a divalent metal ion in the